1. Academic Validation
  2. Overexpression of novel lncRNA NLIPMT inhibits metastasis by reducing phosphorylated glycogen synthase kinase 3β in breast cancer

Overexpression of novel lncRNA NLIPMT inhibits metastasis by reducing phosphorylated glycogen synthase kinase 3β in breast cancer

  • J Cell Physiol. 2019 Jul;234(7):10698-10708. doi: 10.1002/jcp.27738.
Yang Jiang 1 Lili Lin 1 Shen Zhong 2 Yangjun Cai 1 Fen Zhang 1 Xiaobo Wang 1 Rongrong Miao 1 Baodan Zhang 1 Shenmeng Gao 3 Xiaoqu Hu 1
Affiliations

Affiliations

  • 1 Department of Thyroid and Breast surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
  • 2 Department of Colorectal and Anal Surgery, Kecheng People's Hospital, Quzhou, Zhejiang, China.
  • 3 Laboratory of Internal Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
Abstract

Long noncoding RNAs (lncRNAs) are considered as regulators of gene expression in cancers. However, Cancer profiling has little focused on noncoding genes. Here, we reported that RP11-115N4.1 (here renamed novel lncRNA inhibiting proliferation and metastasis [NLIPMT]) was downregulated in breast Cancer tissues. Ectopic expression of NLIPMT inhibited mammary cell proliferation, motility in vitro. Moreover, lnc-NLIPMT reduced the growth of implanted MDA-MB-231 cells in vivo. Mechanistically, glycogen synthase kinase 3β (GSK3β) was identified as an effector protein regulated by lnc-NLIPMT. Inhibition of GSK3β activity restored NLIPMT-induced inhibition of proliferation and motility in breast Cancer cells. These data reveal that lnc-NLIPMT functions as a driver of breast Cancer progression and might serve as a potential target for antimetastatic therapies.

Keywords

breast cancer; glycogen; long noncoding RNA; migration; proliferation; synthase kinase 3β.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-12292
    99.61%, GSK-3β Inhibitor